KR102024125B1 - 스크리닝 방법 및 이의 용도 - Google Patents

스크리닝 방법 및 이의 용도 Download PDF

Info

Publication number
KR102024125B1
KR102024125B1 KR1020147010622A KR20147010622A KR102024125B1 KR 102024125 B1 KR102024125 B1 KR 102024125B1 KR 1020147010622 A KR1020147010622 A KR 1020147010622A KR 20147010622 A KR20147010622 A KR 20147010622A KR 102024125 B1 KR102024125 B1 KR 102024125B1
Authority
KR
South Korea
Prior art keywords
ligand
target
ligands
differentially
expressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147010622A
Other languages
English (en)
Korean (ko)
Other versions
KR20140080504A (ko
Inventor
비욘 프렌데우스
제니 맷슨
Original Assignee
바이오인벤트 인터내셔날 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오인벤트 인터내셔날 에이비 filed Critical 바이오인벤트 인터내셔날 에이비
Publication of KR20140080504A publication Critical patent/KR20140080504A/ko
Application granted granted Critical
Publication of KR102024125B1 publication Critical patent/KR102024125B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
KR1020147010622A 2011-09-22 2012-09-20 스크리닝 방법 및 이의 용도 Active KR102024125B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1116364.9 2011-09-22
GBGB1116364.9A GB201116364D0 (en) 2011-09-22 2011-09-22 Screening methods and uses thereof
PCT/EP2012/068576 WO2013041643A1 (en) 2011-09-22 2012-09-20 Screening methods and uses thereof

Publications (2)

Publication Number Publication Date
KR20140080504A KR20140080504A (ko) 2014-06-30
KR102024125B1 true KR102024125B1 (ko) 2019-09-23

Family

ID=44937671

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147010622A Active KR102024125B1 (ko) 2011-09-22 2012-09-20 스크리닝 방법 및 이의 용도

Country Status (17)

Country Link
US (1) US10191049B2 (https=)
EP (1) EP2758532B1 (https=)
JP (2) JP6370220B2 (https=)
KR (1) KR102024125B1 (https=)
CN (2) CN107663238A (https=)
AU (1) AU2012311542B2 (https=)
CA (1) CA2848932C (https=)
DK (1) DK2758532T3 (https=)
ES (1) ES2690783T3 (https=)
GB (1) GB201116364D0 (https=)
HU (1) HUE040567T2 (https=)
IN (1) IN2014DN01795A (https=)
PL (1) PL2758532T3 (https=)
PT (1) PT2758532T (https=)
RU (1) RU2622089C2 (https=)
SI (1) SI2758532T1 (https=)
WO (1) WO2013041643A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2392723B (en) 2002-09-04 2005-01-12 Bioinvent Int Ab Screening methods
WO2011140241A2 (en) 2010-05-04 2011-11-10 The General Hospital Corporation Methods and compositions for preserving tissues and organs
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof
JP6465407B2 (ja) * 2013-11-22 2019-02-06 株式会社Ｍｏｌｃｕｒｅ 標的分子に結合するポリペプチドの決定方法及び決定システム
EP3698628A1 (en) 2014-08-07 2020-08-26 The General Hospital Corporation Stabilization of whole blood samples
CN109651506B (zh) * 2017-10-11 2021-12-07 上海交通大学 一种快速获得抗原特异性抗体的方法
CN119384696A (zh) * 2022-06-13 2025-01-28 生物发明国际公司 分离反配体的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004023140A1 (en) * 2002-09-04 2004-03-18 Bioinvent International Ab Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366862A (en) 1990-02-14 1994-11-22 Receptor Laboratories, Inc. Method for generating and screening useful peptides
AU8081491A (en) 1990-06-01 1991-12-31 Cetus Corporation Compositions and methods for identifying biologically active molecules
AU1378495A (en) 1993-12-27 1995-07-17 Hamilton Civic Hospitals Research Development, Inc. Methods and compositions for inhibiting thrombogenesis
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
WO2000052054A2 (en) 1999-03-01 2000-09-08 Genentech, Inc. Antibodies for cancer therapy and diagnosis
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
AU2002220236A1 (en) 2000-11-09 2002-05-21 Bionova Pharmaceutials, Inc. A method for identifying the proteome of cells using an antibody library microarray
CN100575489C (zh) 2003-05-14 2009-12-30 多曼蒂斯有限公司 从多肽全能文库恢复可逆可解折叠多肽的方法
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
GB0422431D0 (en) * 2004-10-08 2004-11-10 Affitech As Method
EP2254909A4 (en) 2007-12-21 2012-05-02 Ca Nat Research Council NON-AGGREGATING HUMANS VH DOMAINS
GB201116364D0 (en) 2011-09-22 2011-11-02 Bioinvent Int Ab Screening methods and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004023140A1 (en) * 2002-09-04 2004-03-18 Bioinvent International Ab Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
mAbs, Vol. 3:1, p. 17-20 (2011.01.01.)*

Also Published As

Publication number Publication date
EP2758532A1 (en) 2014-07-30
RU2622089C2 (ru) 2017-06-09
JP2018154627A (ja) 2018-10-04
HK1200486A1 (en) 2015-08-07
KR20140080504A (ko) 2014-06-30
PT2758532T (pt) 2018-11-07
PL2758532T3 (pl) 2018-12-31
EP2758532B1 (en) 2018-07-11
ES2690783T3 (es) 2018-11-22
HUE040567T2 (hu) 2019-03-28
US20140227249A1 (en) 2014-08-14
CA2848932A1 (en) 2013-03-28
AU2012311542B2 (en) 2017-09-21
DK2758532T3 (en) 2018-10-22
WO2013041643A1 (en) 2013-03-28
US10191049B2 (en) 2019-01-29
AU2012311542A1 (en) 2014-03-20
JP2015501289A (ja) 2015-01-15
GB201116364D0 (en) 2011-11-02
IN2014DN01795A (https=) 2015-05-15
CA2848932C (en) 2020-12-29
SI2758532T1 (sl) 2018-12-31
CN107663238A (zh) 2018-02-06
RU2014115956A (ru) 2015-10-27
CN103827302A (zh) 2014-05-28
JP6370220B2 (ja) 2018-08-08

Similar Documents

Publication Publication Date Title
KR102024125B1 (ko) 스크리닝 방법 및 이의 용도
CN108017712A (zh) 一种鲨鱼抗体来源的蛋白骨架及其应用
CN105378479A (zh) 用于预测免疫疗法的临床效果的方法
US10351970B2 (en) Method for screening anti-ligand libraries for identifying anti-ligands specific for differentially and infrequently expressed ligands
CN118994316A (zh) 一种靶向ido1的多肽以及ido1蛋白降解靶向嵌合体
US20260018241A1 (en) Methods of isolating anti-ligands
CN107446021A (zh) 叶酸受体α特异性结合肽5及其应用
IL181928A (en) Methods for screening a library of molecules
De Plano Phage Display as a tool for Marker Discovery, Diagnosis and Targeted Therapy
CN107674115A (zh) 叶酸受体α特异性结合肽3及其应用
CN107793471A (zh) 叶酸受体α特异性结合肽4及其应用
US20050137136A1 (en) Biospecific probes against Salmonella
HK40117257A (zh) 分离反配体的方法
JP6175144B2 (ja) 分子のプールの選択方法
Sang The Use of Phage Display to Identify Specific Peptide Ligands
HK1105451B (en) Methods for antibody library screening

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20220818

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7